Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;8(5):e2512926.
doi: 10.1001/jamanetworkopen.2025.12926.

Enhancing Multicenter Trials With the Trial Innovation Network's Initial Consultation Process

Paul A Harris  1   2 , Consuelo H Wilkins  1   3   4 , Karen Lane  5 , Gordon R Bernard  1   3 , Jonathan D Casey  1   3 , Daniel E Ford  5   6 , Salina P Waddy  7 , Ken L Wiley Jr  7 , Terri L Edwards  1 , Nichol McBee  5 , Dixie D Thompson  8   9 , Mary Stroud  1 , Emily Serdoz  1 , Nan Kennedy  1 , Sarah J Nelson  1 , Michelle Jones  1 , Lindsay M Eyzaguirre  5 , Leslie R Boone  1 , Jessica Baird  5 , Colleen Lawrence  1 , Elizabeth Holthouse  5 , Sarah K Cook  1 , Maeve Tischbein  1 , Natalya Amrine  1 , Tiffany Chen  1 , Jodie Cohen  1 , LaShondra Deyampert  1 , Natalie Dilts  1 , Delicia Burts  1 , Amna Baig  1 , Joseph Christodoulou  1 , Mariela Rodriguez  1 , Edgar R Miller 3rd  5 , James F Casella  5   6 , W Andrew Mould  5 , J Michael Dean  8 , Daniel K Benjamin Jr  10 , Harry P Selker  11   12 , Marisha E Palm  11   12 , Lori Poole  13 , Jeri S Burr  8 , Sara Hassani  7 , Angeline Nanni  6 , Meghan Hildreth  6 , Daniel F Hanley  5   6
Affiliations

Enhancing Multicenter Trials With the Trial Innovation Network's Initial Consultation Process

Paul A Harris et al. JAMA Netw Open. .

Erratum in

  • Error in Author Affiliations.
    [No authors listed] [No authors listed] JAMA Netw Open. 2025 Jul 1;8(7):e2525918. doi: 10.1001/jamanetworkopen.2025.25918. JAMA Netw Open. 2025. PMID: 40632540 Free PMC article. No abstract available.
No abstract available

Plain language summary

This qualitative study describes the Trial Innovation Network's initial consultation process, which provides researchers with resources and recommendations to address complex aspects of planning and conducting clinical trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Wilkins reported receiving grants from Patient Centered Outcomes Research Institute during the conduct of the study. Dr Casey reported receiving a travel grant from Fisher and Paykel Travel to speak at a conference outside the submitted work. Dr Ford reported receiving grants from Johns Hopkins University School of Medicine during the conduct of the study. Dr Casella reported grants from the US Centers for Disease Control and Prevention, Maternal and Child Health Bureau, and the state of Maryland and having a patent for a panel of biomarkers for detection of brain injury with royalties paid from ImmunArray and a patent for aptamers for treatment of sickle cell disease issued outside the submitted work. Dr Benjamin reported receiving personal fees from AbbVie, PPD, and Syneos Health outside the submitted work. Dr Hanley reported receiving stock options from Epiwatch during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Schematic of Initial Consultation Process
PAT, Proposal Assessment Team; PI, principal investigator; RIC, Recruitment Innovation Center; TIC, Trial Innovation Center; TIN, Trial Innovation Network.
Figure 2.
Figure 2.. Trial Innovation Network (TIN) Initial Consultation Metrics
IRB indicates institutional review board; RIC, Recruitment Innovation Center; TIC, Trial Innovation Center. aNet promoter score (NPS) = % promoters − % detractors. Individual NPSs were averaged across all 3 questions for a total mean NPS. The NPS is interpreted as good (ie, any positive score above 0), excellent (ie, a score of 50-69), or world class (a score of ≥70). NPS scores are aggregated across all TICs/RIC and by individual TICs/RIC in instances where the principal investigator voluntarily self-identifies as part of the survey.
See this image and copyright information in PMC

References

    1. Bernard GR, Harris PA, Pulley JM, et al. A collaborative, academic approach to optimizing the national clinical research infrastructure: the first year of the Trial Innovation Network. J Clin Transl Sci. 2018;2(4):187-192. doi: 10.1017/cts.2018.319 - DOI - PMC - PubMed
    1. Harris PA, Dunsmore SE, Atkinson JC, et al. ; Trial Innovation Network . Leveraging the expertise of the CTSA program to increase the impact and efficiency of clinical trials. JAMA Netw Open. 2023;6(10):e2336470. doi: 10.1001/jamanetworkopen.2023.36470 - DOI - PMC - PubMed
    1. Wilkins CH, Edwards TL, Stroud M, et al. The recruitment innovation center: developing novel, person-centered strategies for clinical trial recruitment and retention. J Clin Transl Sci. 2021;5(1):e194. doi: 10.1017/cts.2021.841 - DOI - PMC - PubMed
    1. What is net promoter. Net Promoter. Accessed July 2, 2024. https://www.netpromoter.com/know/
    1. Lane K, Palm ME, Marion E, et al. Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network. J Clin Transl Sci. 2023;7(1):e131. doi: 10.1017/cts.2023.560 - DOI - PMC - PubMed